Companies › Chongqing Peg-Bio Biopharm
5 active drug programs in 6 registered trials: 4 Phase 1, 1 Phase 3, 1 Phase 2; Gastroenterology, Oncology, Metabolic and endocrine, Hematology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PJ009 Glucagon-like peptide-2 (GLP-2) receptor agonist | GLP2R | Phase 3 | Short Bowel Syndrome | Mar 2027 |
| FT1 | – | Phase 2 | Short Bowel Syndrome | Apr 2027 |
| PA5 Pegylated Arginine Deiminase Dimer | ADI1 | Phase 1 | Advanced Solid Tumors | Feb 2027 |
| PL54 PEGylated recombinant phenylalanine ammonia-lyase | PAH | Phase 1 | Phenylketonuria (PKU) | Jun 2027 |
| PN20 thrombopoietin receptor agonist | THPO | Phase 1 | Primary Immune Thrombocytopenia (ITP); Thrombocytopenia Associated With Chronic Liver Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06880081 | PN20 | Phase 1 | Primary Immune Thrombocytopenia (ITP) | Hematology | Feb 2026 |
| NCT07446491 | PN20 | Phase 1 | Thrombocytopenia Associated With Chronic Liver Disease | Hematology | Oct 2026 |
| NCT07702162 | PA5 | Phase 1 | Advanced Solid Tumors | Oncology | Feb 2027 |
| NCT06512584 | PJ009 | Phase 3 | Short Bowel Syndrome | Gastroenterology | Mar 2027 |
| NCT07704047 | FT1 | Phase 2 | Short Bowel Syndrome | Gastroenterology | Apr 2027 |
| NCT07672756 | PL54 | Phase 1 | Phenylketonuria (PKU) | Metabolic and endocrine | Jun 2027 |
BioMarin Pharmaceutical PTC Therapeutics NGGT Agios Pharmaceuticals NGGT (Suzhou) Biotechnology VectivBio Takeda Geropharm MIBIO PTE. Sichuan Clover Biopharmaceuticals
Ipsen VectivBio Zhejiang Doer Biologics Dong-A ST Hanmi Pharmaceutical Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.